CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more

In practice

News and in-depth features about business management and career development in optics

Find out more


Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Treatment for rare allergic eye condition launched

Santen has released ciclosporin eye drops for the treatment of severe vernal keratoconjunctivitis

Brown eye

A treatment has been launched for the severe allergic eye condition, vernal keratoconjunctivitis (VKC).

Pharmaceutical company, Santen, has released Verkazia for the treatment of VKC in children from four years of age to adolescents.

Verkazia significantly improved damage to the surface of the eye and reduced symptoms of severe VKC in a phase III trial.

There was a 68% improvement in photophobia, 58% improvement in tearing, 72% improvement in itching and 67% improvement in mucous discharge compared to controls.

The eye drop emulsion contains 0.1% ciclosporin. The recommended dose of Verkazia will be one drop administered four times a day in each affected eye.

The European Commission granted approval for Verkazia in July 2018 as an orphan medicinal product for severe VKC. The condition holds rare disease status in Europe.